Investor Presentaiton
BION-206 Target Product Profile
自
Product Description
Antibody fragment targeting the CD28 receptor
BIOND
BIOLOGICS
{!
.
Scientific Rationale
MOA/Clinical Pharmacology
CD28 receptor is shed from activated T cells.
The soluble forms serve as a decoy receptor and
were found in the serum of cancer patients
Soluble CD28 was found to inhibit T cells
activity, and attenuate the activation signal of
anti-PD-1 blockade
The identified CD28-cleaving MMPs are known
to be highly expressed in tumor tissues
BION-206 binds to the shedding region of CD28
and sterically hinders access for MMPs
BION-206 is designed to augment T cells
activation, particularly memory T cells
Strategic Context /
Differentiation
Indication(s) and patient
3 population
•
•
A novel regulatory mechanism in the
CD28/B7 axis (1st in class)
Has the potential to overcome PD-1
resistance
•
Solid tumors with immune infiltration in patients
with unresectable or metastatic disease,
including anti-PD1 refractory patients
# Stage
Pre-clinic
Biond Biologics Corporate Presentation | May 2021 | Non-confidential
श्र
23View entire presentation